⚕ For healthcare professionals & patients — informational use only, not a substitute for medical advice. 15,548 products indexed

VELBASTINE

VINBLASTINE SULFATE · by AL-HABIB

ANTINEOPLASTICS Vinca alkaloid AL-HABIB

Composition

Inj 10 mg: Vinblastine sulphate 10 mg; vial.

Indications & Dosage

Hodgkins disease, Lymphocytic lymphoma, Histiocytic lymphoma, Advanced mycosis fungoides, Advanced testicular cancer, Kaposis sarcoma, LettererSiwe disease, Resistant choriocarcinoma, Unresponsive breast cancer: BY IV INJ OR INF: Adults: At weekly intervals:1st dose=3.7 mg/m2, 2nd dose=5.5 mg/m2, 3rd dose=7.4 mg/m2, 4th dose=9.25 mg/m2, 5th dose= 11.1 mg/m2, increase to a max 18.5 mg/m2. Children: At weekly intervals: 1st dose=2.5 mg/ rn2, 2nd dose=3.75 mg/m2, 3rd dose=5 mg/m2, 4th dose=6.25 mg/m2, 5th dose= 7.5 mg/m2, increase to a max 12.5 mg/m2.

Administration

For IV administration only, usually as a slow (2-3 min) push, or a bolus (5-15 min) infusion. It is occasionally given as a 24-hour continuous infusion. Reconstitute to a cone of 1 mg/ml with bacteriostatic water, bacteriostatic NS, SWFI, NS, or D5W; for infusion, may be diluted with 50-1000 ml NS or D5W.

Compatibility

Stable in D5W, LR, NS, bacteriostatic water.

Contraindications

Bone marrow suppression.

Precautions

Intrathecal administration can cause severe neurotoxicity which may result in death.

Interactions

Mitomycin C, CYP3A4 enzyme inhibitors.

Pregnancy

Positive evidence of risk: Avoid

Lactation

Contraindicated. Discontinue breast-feeding

Side Effects

Alopecia, autonomic neuropathy, hyperuricaemia, loss of deep tendon reflexes, motor weakness, myelosuppression(dose-limiting), nausea neurotoxicity, oral mucositis, ototoxicity, peripheral neuropathy, peripheral paraesthesia, severe bronchospasm following administration, severe local irritation, thromboembolism, tumourlysis syndrome, vomiting